Copyright
©The Author(s) 2021.
World J Hepatol. Mar 27, 2021; 13(3): 300-314
Published online Mar 27, 2021. doi: 10.4254/wjh.v13.i3.300
Published online Mar 27, 2021. doi: 10.4254/wjh.v13.i3.300
Table 2 Possible therapeutic strategies for treatment of lymphatic dysfunction in cirrhosis
To decrease formation of lymph | |
Decrease water retention | Low salt diet, diuretic therapy |
Control of portal hypertension | Beta-blocker, octreotide, transjugular intrahepatic portosystemic shunt |
Increase interstitial pressure | Compression therapy |
To promote lymphatic drainage | |
Facilitate fluid movement into the lymphatic vessels | Compression therapy, limb elevation, diuretic therapy (limited role) |
Increase contractility of the lymphatic vessels | Nor-adrenaline, phenylephrine, nitric oxide-inhibitors (experimental) |
Facilitate lysis of interstitial protein | Benzopyrones (coumarin and flavoids) |
Promote lymphangiogenesis | Prostaglandins E2 (experimental), vascular endothelial growth factor-C (experimental) |
To control aggravating factors for lymphatic dysfunction | |
Care of lymphedema | Control of infection (aggressive use of antibiotics), avoidance of trauma, hot bath and other heat-producing treatment |
Control risk factors | Control of diabetes, dyslipidemia and obesity |
To decrease leakage of lymph | |
Decrease stimulants of intestinal lymph flow | Low fat diet, octreotide |
Decrease leakage of lymph by intervention | Compression therapy, antiplasmin (tranexamic acid); radiological intervention to obliterate the site of leak |
To correct underlying condition | |
Definitive therapy of cirrhosis | Liver transplantation |
- Citation: Kumar R, Anand U, Priyadarshi RN. Lymphatic dysfunction in advanced cirrhosis: Contextual perspective and clinical implications. World J Hepatol 2021; 13(3): 300-314
- URL: https://www.wjgnet.com/1948-5182/full/v13/i3/300.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i3.300